Brano Therapeutics Raises $6.8M to Combat Hard-to-Treat Heart Failure

64 million people worldwide live with heart failure. Existing medicines fail nearly half of those patients. Brano Therapeutics, a Duke-NUS spin-off, has secured $6.8 million to advance a molecule that tackles HFpEF at its metabolic root. This work grew from decades of research into why the heart loses its ability to feed itself. Backed by leading investors, the startup aims to redefine cardiovascular care with a targeted therapy for patients who currently lack effective treatment.

Use The App To Win ₦1m

Stories are shared by community members. This article does not represent the official view of NaijaWorld — the author is solely responsible for its content.